9MW1411

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
9MW1411

GtoPdb Ligand ID: 13956

Compound class: Antibody

Comment: 9MW1411 is a clinical stage humanised IgG1 monoclonal antibody that binds to and neutralises Staphylococcus aureus alpha-toxin [1].

No information available.

No information available.

Summary of Clinical Use
9MW1411 was designed to treat bacterial infections caused by S. aureus and progressed to clinical development. Phase 1 (NCT04784312) results have been published [1], with 9MW1411 displaying a favorable safety profile. The status of a Phase 2 trial (NCT05339802), to evaluate the safety and efficacy of 9MW1411 in patients with acute bacterial skin and skin structure infections (ABSSSI) caused by S. aureus, is unknown (as of April 2022).

Summary of Clinical Use

9MW1411 was designed to treat bacterial infections caused by S. aureus and progressed to clinical development. Phase 1 (NCT04784312) results have been published [1], with 9MW1411 displaying a favorable safety profile. The status of a Phase 2 trial (NCT05339802), to evaluate the safety and efficacy of 9MW1411 in patients with acute bacterial skin and skin structure infections (ABSSSI) caused by S. aureus, is unknown (as of April 2022).

Clinical Trials
Clinical Trial ID	Title	Type	Source	Comment	References
NCT04784312	A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection	Phase 1 Interventional	Mabwell (Shanghai) Bioscience Co., Ltd.		1
NCT05339802	A Phase Ⅱ Clinical Study of 9MW1411 Injection in Acute Bacterial Skin and Skin Structure Infections	Phase 2 Interventional	Mabwell (Shanghai) Bioscience Co., Ltd.